455 related articles for article (PubMed ID: 7729331)
1. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.
Markham A; Bryson HM
Drugs; 1995 Feb; 49(2):232-54. PubMed ID: 7729331
[TBL] [Abstract][Full Text] [Related]
2. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
Dunn CJ; Wagstaff AJ
Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
[TBL] [Abstract][Full Text] [Related]
3. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.
Faulds D; Sorkin EM
Drugs; 1989 Dec; 38(6):863-99. PubMed ID: 2693045
[TBL] [Abstract][Full Text] [Related]
4. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.
Dunn CJ; Markham A
Drugs; 1996 Feb; 51(2):299-318. PubMed ID: 8808169
[TBL] [Abstract][Full Text] [Related]
5. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.
Cheer SM; Wagstaff AJ
Drugs; 2004; 64(3):323-46. PubMed ID: 14871172
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract][Full Text] [Related]
7. Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia.
Mercuriali F
Semin Hematol; 1996 Apr; 33(2 Suppl 2):18-20; discussion 21. PubMed ID: 8723576
[TBL] [Abstract][Full Text] [Related]
8. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
[TBL] [Abstract][Full Text] [Related]
9. A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.
Beguin Y
Drug Saf; 1998 Oct; 19(4):269-82. PubMed ID: 9804442
[TBL] [Abstract][Full Text] [Related]
10. Improving the efficacy of preoperative autologous blood donation in patients with low hematocrit: a randomized, double-blind, controlled trial of recombinant human erythropoietin.
Price TH; Goodnough LT; Vogler WR; Sacher RA; Hellman RM; Johnston MF; Bolgiano DC; Abels RI
Am J Med; 1996 Aug; 101(2A):22S-27S. PubMed ID: 8928704
[TBL] [Abstract][Full Text] [Related]
11. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
[TBL] [Abstract][Full Text] [Related]
13. Anemia and epoetin alfa in high-dose chemotherapy programs for breast cancer patients.
Danova M; Ferrari S
Semin Oncol; 2002 Jun; 29(3 Suppl 8):21-5. PubMed ID: 12082650
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
[TBL] [Abstract][Full Text] [Related]
15. Managing cancer-related anaemia with epoetin alfa.
Itri LM
Nephrol Dial Transplant; 2002; 17 Suppl 1():73-7. PubMed ID: 11812917
[TBL] [Abstract][Full Text] [Related]
16. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
17. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
Henry DH
Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma.
Dammacco F; Castoldi G; Rödjer S
Br J Haematol; 2001 Apr; 113(1):172-9. PubMed ID: 11328297
[TBL] [Abstract][Full Text] [Related]
19. Epoetin in cancer-related anaemia.
Ludwig H
Nephrol Dial Transplant; 1999; 14 Suppl 2():85-92. PubMed ID: 10334673
[TBL] [Abstract][Full Text] [Related]
20. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
